Scholarlink

<p>With improving survival in malignancies, the occurrence of multiple myeloma (MM) as a second primary malignancy is being increasingly recognized. Objectives of this study were to describe the clinicopathologic features and outcomes of patients who developed MM following another malignancy. This is a retrospective descriptive case series<b>.</b> There were 8 patients with multiple myeloma as second primary malignancy between 2010 and 2024. The median age at myeloma diagnosis was 68&#xa0;years (range 39–88 years). Primary malignancies included lymphoid neoplasms (n = 3), carcinoma breast (n = 2), carcinoma prostate (n = 1), carcinoma tongue (n = 1), and granulosa cell tumor (n = 1). The median interval between malignancies was 4&#xa0;years (0.8–11&#xa0;years). Most patients presented with symptomatic myeloma; IgG-kappa was the dominant paraprotein (n = 4). Six of eight patients received systemic therapy, and four underwent upfront autologous stem cell transplantation. All transplanted patients achieved sustained remission with follow-up of 47–123&#xa0;months. Two patients died (one of H1N1-related ARDS, one on best supportive care), and one was lost to follow-up. Secondary multiple myeloma following another malignancy is rare. Standard myeloma therapy is feasible and effective in selected patients with prior cancer in remission.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multiple Myeloma as a Second Primary Malignancy

  • 期刊论文

  • 发表日期：

    2026年3月11日

查看全文
  • T. S. Aathira,
  • Vivek Mohan,
  • Diksha Dev Yadav,
  • Rahul Naithani

摘要

With improving survival in malignancies, the occurrence of multiple myeloma (MM) as a second primary malignancy is being increasingly recognized. Objectives of this study were to describe the clinicopathologic features and outcomes of patients who developed MM following another malignancy. This is a retrospective descriptive case series. There were 8 patients with multiple myeloma as second primary malignancy between 2010 and 2024. The median age at myeloma diagnosis was 68 years (range 39–88 years). Primary malignancies included lymphoid neoplasms (n = 3), carcinoma breast (n = 2), carcinoma prostate (n = 1), carcinoma tongue (n = 1), and granulosa cell tumor (n = 1). The median interval between malignancies was 4 years (0.8–11 years). Most patients presented with symptomatic myeloma; IgG-kappa was the dominant paraprotein (n = 4). Six of eight patients received systemic therapy, and four underwent upfront autologous stem cell transplantation. All transplanted patients achieved sustained remission with follow-up of 47–123 months. Two patients died (one of H1N1-related ARDS, one on best supportive care), and one was lost to follow-up. Secondary multiple myeloma following another malignancy is rare. Standard myeloma therapy is feasible and effective in selected patients with prior cancer in remission.